{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:04:54Z","timestamp":1772809494299,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie Biotherapeutics Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40120-016-0048-2","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T14:56:43Z","timestamp":1468421803000},"page":"169-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program"],"prefix":"10.1007","volume":"5","author":[{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Stefoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Selmaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Holman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Tornesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surekha","family":"Akella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McCroskery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/1744666X.2013.811046","volume":"9","author":"A Ghezzi","year":"2013","unstructured":"Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol. 2013;9:683\u201391 (quiz 92).","journal-title":"Expert Rev Clin Immunol"},{"key":"48_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/ern.13.12","volume":"13","author":"E Lu","year":"2013","unstructured":"Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13:251\u201360 (quiz 61).","journal-title":"Expert Rev Neurother"},{"key":"48_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13311-012-0147-4","volume":"10","author":"B Bielekova","year":"2013","unstructured":"Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55\u201367.","journal-title":"Neurotherapeutics"},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneurol.2013.95","volume":"9","author":"H Wiendl","year":"2013","unstructured":"Wiendl H, Gross CC. Modulation of IL-2R\u03b1 with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394\u2013404.","journal-title":"Nat Rev Neurol"},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2249.2007.03555.x","volume":"151","author":"L Airas","year":"2008","unstructured":"Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H, Finnish Multiple Sclerosis and Pregnancy Study Group. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008;151:235\u201343.","journal-title":"Clin Exp Immunol"},{"key":"48_CR6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458\u201365.","journal-title":"Immunology"},{"key":"48_CR7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2249.2001.01487.x","volume":"124","author":"HP Brok","year":"2001","unstructured":"Brok HP, Tekoppele JM, Hakimi J, et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol. 2001;124:134\u201341.","journal-title":"Clin Exp Immunol"},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4049\/jimmunol.158.1.452","volume":"158","author":"Y Guex-Crosier","year":"1997","unstructured":"Guex-Crosier Y, Raber J, Chan CC, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997;158:452\u20138.","journal-title":"J Immunol"},{"key":"48_CR9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1474-4422(14)70039-0","volume":"13","author":"G Giovannoni","year":"2014","unstructured":"Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472\u201381.","journal-title":"Lancet Neurol"},{"key":"48_CR10","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","volume":"381","author":"R Gold","year":"2013","unstructured":"Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167\u201375.","journal-title":"Lancet"},{"key":"48_CR11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418\u201328.","journal-title":"N Engl J Med"},{"key":"48_CR12","doi-asserted-by":"crossref","unstructured":"Radue E-W, Giovannoni G, Gold R, et al. Long-term efficacy of daclizumab HYP in relapsing-remitting multiple sclerosis: 3 year results from the SELECTED extension study. Presented at 67th Annual Meeting of the Academy of Neurology, 18\u201325 April 2015; Washington, DC, USA.","DOI":"10.1212\/WNL.84.14_supplement.P7.226"},{"key":"48_CR13","doi-asserted-by":"crossref","unstructured":"Gold R, Giovannoni G, Selmaj K, et al. Long-term safety of daclizumab HYP in patients with relapsing-remitting multiple sclerosis: 3\u20134\u00a0year results from the SELECTED extension study [poster P7.225]. Presented at 67th Annual Meeting of the American Academy of Neurology, 18\u201325 April 2015, Washington, DC, USA.","DOI":"10.1212\/WNL.84.14_supplement.P7.225"},{"key":"48_CR14","unstructured":"Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability of daclizumab HYP in patients with relapsing-remitting multiple sclerosis: an integrated analysis of six clinical studies [poster P554]. Presented at 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 7\u201310 Oct 2015, Barcelona, Spain."},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/aje\/kwt334","volume":"179","author":"BL Pineles","year":"2014","unstructured":"Pineles BL, Park E, Samet JM. Systematic review and meta-analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol. 2014;179:807\u201323.","journal-title":"Am J Epidemiol"},{"key":"48_CR16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdrb.20234","volume":"89","author":"P Jarvis","year":"2010","unstructured":"Jarvis P, Srivastav S, Vogelwedde E, Stewart J, Mitchard T, Weinbauer GF. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Res B Dev Reprod Toxicol. 2010;89:175\u201387.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"48_CR17","first-page":"29","volume":"47","author":"J Tsuchida","year":"2008","unstructured":"Tsuchida J, Yoshida T, Sankai T, Yasutomi Y. Maternal behavior of laboratory-born, individually reared long-tailed macaques (Macaca fascicularis). J Am Assoc Lab Anim Sci. 2008;47:29\u201334.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/GCO.0000000000000156","volume":"27","author":"M Delnord","year":"2015","unstructured":"Delnord M, Blondel B, Zeitlin J. What contributes to disparities in the preterm birth rate in European countries? Curr Opin Obstet Gynecol. 2015;27:133\u201342.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-014-0159-9","volume":"53","author":"AA Othman","year":"2014","unstructured":"Othman AA, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014;53:907\u201318.","journal-title":"Clin Pharmacokinet"},{"key":"48_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1352458510394610","volume":"17","author":"M Sandberg-Wollheim","year":"2011","unstructured":"Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17:423\u201330.","journal-title":"Mult Scler"},{"issue":"S30","key":"48_CR21","first-page":"006","volume":"80","author":"S Tomczyk","year":"2013","unstructured":"Tomczyk S, Sperling B. Pregnancy outcomes in patients exposed to intramuscular interferon beta-1a (IM IFN\u03b2-1a). Neurology. 2013;80(S30):006.","journal-title":"Neurology."},{"key":"48_CR22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/jnnp-2014-308113","volume":"86","author":"RS Romero","year":"2015","unstructured":"Romero RS, Lunzmann C, Bugge JP. Pregnancy outcomes in patients exposed to interferon beta-1b. J Neurol Neurosurg Psychiatry. 2015;86:587\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"48_CR23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2377-12-124","volume":"12","author":"M Giannini","year":"2012","unstructured":"Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124.","journal-title":"BMC Neurol"},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","volume":"21","author":"N Ebrahimi","year":"2015","unstructured":"Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198\u2013205.","journal-title":"Mult Scler"},{"issue":"P02","key":"48_CR25","first-page":"127","volume":"80","author":"L Cristiano","year":"2013","unstructured":"Cristiano L, Friend S, Bozic C, Bloomgren G. Evaluation of pregnancy outcomes from the TYSABRI\u00ae (Natalizumab) pregnancy exposure registry. Neurology. 2013;80(P02):127.","journal-title":"Neurology"},{"key":"48_CR26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","volume":"82","author":"G Karlsson","year":"2014","unstructured":"Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674\u201380.","journal-title":"Neurology"},{"key":"48_CR27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40120-014-0020-y","volume":"3","author":"BC Kieseier","year":"2014","unstructured":"Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014;3:133\u20138.","journal-title":"Neurol Ther"},{"key":"48_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40120-015-0033-1","volume":"4","author":"R Gold","year":"2015","unstructured":"Gold R, Phillips T, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4:93\u2013104.","journal-title":"Neurol Ther"},{"key":"48_CR29","unstructured":"McCombe P, Achiron A, Giovannoni G, et al. Pregnancy outcomes in the alemtuzumab multiple sclerosis clinical development program. Presented at the Joint ACTRIMS-ECTRIMS Meeting, 10\u201313 Oct 2014, Boston, MA, USA."},{"key":"48_CR30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40263-015-0238-y","volume":"29","author":"MP Amato","year":"2015","unstructured":"Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2015;29:207\u201320.","journal-title":"CNS Drugs"},{"key":"48_CR31","doi-asserted-by":"publisher","unstructured":"Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers and subjects with multiple sclerosis: analysis of phase I\u2013III clinical trials [published online 12 Feb 2016]. Clin Pharmacokinet. doi: 10.1007\/s40262-016-0366-7 .","DOI":"10.1007\/s40262-016-0366-7"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-016-0048-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:55:15Z","timestamp":1748998515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-016-0048-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s40120-016-0048-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]}}}